HLA allelic variants and carbamazepine-induced hypersensitivity

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 5, 2013, Pages 386-387

  Grover, S ^a   Kukreti, R ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; HLA A ANTIGEN;

DRUG HYPERSENSITIVITY; DRUG QUALITY; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTYPE; HLA SYSTEM; HUMAN; LETTER; MEDICAL LITERATURE; PRIORITY JOURNAL; QUALITY CONTROL; SKIN ALLERGY;

EID: 84876690576     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.264     Document Type: Letter

References (5)

1. Yip, V.L., Marson, A.G., Jorgensen, A.L., Pirmohamed, M. & Alfrevic, A. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin. Pharmacol. Ther. 92, 757-765 (2012).
2. Kulkantrakorn, K. et al. HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain. Pain Pract. 12, 202-208 (2012).
3. Tassaneeyakul, W. et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 51, 926-930 (2010).
4. Kim, S.H. et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res. 97, 190-197 (2011).
5. Hung, S.I. et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16, 297-306 (2006).